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Abstract 
The discovery that pericytes are in vivo counterparts of Mesenchymal Stem/Stromal Cells 
(MSCs) has placed these perivascular cells in the research spotlight, bringing up hope for a well-
characterized cell source for clinical applications, alternative to poorly-defined, heterogeneous 
MSCs preparations currently in use. Native pericytes express typical MSC markers and, after 
isolation by fluorescence-activated cell sorting, display an MSC phenotype in culture. These 
features have been demonstrated in different species, including humans and horses, the main 
targets of regenerative treatments. Significant clinical potential of pericytes has been shown by 
transplantation of human cells into rodent models of tissue injury, and it is hoped that future 
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studies will demonstrate clinical potential in veterinary species. Here, we provide an overview of 
the current knowledge on pericytes across different species including humans, companion and 
large animal models, in relation to their identification in different body tissues, methodology for 
prospective isolation, characterization and potential for tissue regeneration.  
 
Key terms: Pericyte, veterinary, CD146, regenerative medicine, mesenchymal stem cells, human, 
horse, dog 
 
 
 
 
Introduction 
Pericytes were initially described as ‘Rouget cells’ by Eberth and Rouget (1,2) at the end of the 
19th century, and were renamed by Zimmerman as ‘pericytes’ (3). However, other designations, 
although less specific, such as ‘mural cells’ (4-6) and ‘CD146+ cells’ (7,8), are also in use. Pericytes 
localize across the body around the endothelial layer in capillaries and microvessels, where they 
are embedded within the basement membrane and can be identified based on the expression of 
markers including CD146 (cluster of differentiation 146; MCAM, melanoma cell adhesion 
molecule), PDGFRβ (CD140b, platelet derived growth factor receptor beta), NG2 (neural/glial 
antigen 2; CSPG4, chondroitin sulfate proteoglycan 4) and αSMA (alpha smooth muscle actin; 
ACTA1, actin alpha 1 skeletal muscle), although these markers are not all-inclusive of the pericyte 
compartment. Pericytes play fundamental roles in angiogenesis and blood vessel homeostasis 
and function, being critical for regulation of blood vessel integrity and permeability, and blood 
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flow (4,9). In addition, the wide distribution of pericytes in close association with the body 
vasculature (Fig. 1) positions these cells at the forefront of endogenous tissue repair responses, 
in which they have been shown to be actively involved either directly by differentiating into 
specialized mesenchymal-lineage cells or indirectly by cell-to-cell interactions or release of 
paracrine mediators including those related to angiogenesis and immunoregulation, two 
fundamental processes for tissue repair and regeneration (10-12). 
Interest in pericyte biology has been in the rise since their link with Mesenchymal 
Stem/Stromal Cells (MSCs) was identified (13-19). In parallel, the use of MSCs in regenerative 
medicine has been gaining momentum, as demonstrated by the number of clinical trials currently 
underway worldwide (658 registered trials in the NIH in USA alone) and the approval of their use 
already in several applications, namely, pediatric graft versus host disease (in Canada), 
degenerative arthritis and orthopedics (South Korea and USA), Crohn’s disease (South Korea) and 
post-acute myocardial infarction (South Korea and India) (20,21) and ongoing clinical trials using 
mesoangioblasts (a pericyte subset) in dystrophic patients (22). Other than humans, interest in 
the clinical use of MSCs has been very significant in the horse (23-26), followed by dog (27-29) 
and cat (30-32). Indeed, although not always based on solid scientific and clinical evidence, a vast 
number of horses have been treated worldwide and continue to be treated every year for specific 
orthopedic conditions using different types of MSC preparations, providing a unique pre-clinical 
model for human therapies (23,33,34). Research in veterinary MSCs started around 20 years ago 
with the characterization of equine bone marrow BM-MSCs (35) followed shortly after by the 
first clinical studies in horses (25,26); interest in equine MSCs has since increased steadily 
resulting in around 400 publications at present.  
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In all species, MSCs for clinical use are obtained by in vitro expansion of relatively rare 
stem/progenitor cell populations in tissue extracts from bone marrow, adipose tissue or, less 
frequently, placenta or umbilical cord. Adipose tissue yields higher amount of MSC cells and is of 
easier accessibility than bone marrow, being more attractive for clinical use. Although reports 
indicate variation on the properties between these two tissue sources, the results did not always 
agree between studies, reflecting the heterogeneity between cell preparations what may also 
result from method of extraction, culture conditions, age and gender of donor (36). MSCs are 
applied either as crude cell extracts or, given their low abundance in native tissues, following 
expansion in culture to obtain sufficient cells for clinical use. Either way, cell preparations used 
clinically are heterogeneous in nature (37) and contain variable amounts of stem/progenitor cells 
and occasionally other contaminant cell types raising important issues regarding standardization 
and consistency of cell harvesting methods, and efficacy of treatments. As most of the research 
in this area has been performed with MSCs, it is not completely clear at the moment what cell 
sub-sets or combinations of these will be more appropriate for the diverse tissue regenerative 
applications. Systematic studies involving MSCs sub-populations are underway and more work 
will be needed to answer these crucial questions in order to obtain effective, reliable and 
consistent cell therapies (38-40). Therefore, despite guidelines from The International Society for 
Cellular Therapy (ISCT) defining the characteristics of culture-derived human MSC preparations 
(41-43), there has long been a clear interest to identify and characterize MSC sub-populations in 
their native form, i.e., before expansion in vitro. In the absence of specific criteria, ISCT guidelines 
are used to define MSCs from veterinary species, which does not account for species-specific 
differences, for example in relation to expression of cell surface antigens. In addition, because of 
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the lack of species-specific antibodies (34,44), cross-reactivity with MSC and pericyte markers 
needs to be established in each case. These challenges have hampered the identification, 
isolation and characterization of native MSC populations from veterinary species. 
 
A perivascular source of MSCs 
A link between MSCs and blood vessel walls was demonstrated by studies in which cells with 
MSC features, including expression of specific markers (CD29, CD44, CD90), multipotency and 
clonogenicity, were obtained from human saphena (45) and aorta (46), as well as by the 
demonstration that fetal mesangioblasts (a  cell with pericyte characteristics) (47) and adult 
pericytes (48) can differentiate into distinct mesenchymal lineages. More definite proof of a 
perivascular origin of MSCs was provided by seminal studies showing that pericytes in different 
human tissues stained for classical MSC markers and, upon in vitro expansion, displayed an MSC 
phenotype while maintaining the expression of pericyte markers (CD146, PDGFRβ, NG2, αSMA). 
These findings have more recently extended to horse, dog and sheep (8,49-52), overall indicating 
that pericytes are in vivo counterparts of culture-expanded MSCs in different species (13,39,53).  
Some of the previous studies (8,54) also identified a population of adventitial cells (marked by 
the expression of CD34) as a perivascular cell type (in addition to pericytes) with MSC properties, 
and proposed these adventitial cells to be precursors of pericyte (54). However, relatively less 
attention has been paid to the MSC biology and regenerative potential of adventitial cells, and 
will not be discussed in this review.  
Multipotency is a central property of MSCs and cell lineage tracking studies have shown that 
pericytes are indeed able to differentiate into different mesenchymal lineages in vivo. Thus, using 
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Cre-mediated PDGFRβ-reporter mouse strains, it was shown that PDGFRβ-positive cells acted as 
adipocyte precursors in vitro and when transplanted into nude mice (55), in addition to giving 
rise to follicular dendritic cells capable of trapping immune complexes and recruiting B cells (56). 
Moreover, pericytes transgenically labelled with an inducible Alkaline Phosphatase CreERT2 
contributed to growth and regeneration of skeletal muscle by fusing with developing myofibers 
in mice, a response that was significantly increased upon injury or in chronically regenerating 
dystrophic muscle (48,57). A subset of pericytes expressing PDGFRβ also contributes to fibrosis, 
as observed in a tamoxifen-inducible Glast-CreER YFP reporter mice in which spinal cord injury 
resulted in recruitment of labelled cells expressing fibronectin that formed the core of the scar 
(58). During tooth growth and in response to injury in vivo, some pericytes traced by using NG2-
Cre reporter mice contribute to odontoblast production, but did not account for all cell 
differentiation (59), although not all pericytes express NG2 (13). In contrast to these reports, a 
recent lineage-tracing study using an inducible Tbx18-CreERT2 mouse showed that pericytes and 
vascular smooth muscle cells maintained their identity during aging without significantly 
contributing to tissue regeneration responses by giving rise to adipocytes, myocytes or fibrosis, 
despite being multipotent and showing MSCs properties in vitro (60). These discrepancies may 
have resulted from the use of different lineage-tracing strategies resulting in the selection of 
different subset(s) of pericytes, some of which may not intrinsically act as mesenchymal 
progenitors (61), perhaps depending on their organ of origin and developmental stage (62). It 
also needs to be considered that mesenchymal precursors involved in tissue regeneration 
responses may include cells other than pericytes (16,59,63,64). 
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Prospective isolation and characterization of pericytes 
The suggestion that pericytes were a native source of MSCs provided a strong drive for 
developing strategies to isolate and culture these cells as an alternative to the heterogeneous 
MSC populations used clinically. Using fluorescence-activated cells sorting (FACS), Sacchetti et al. 
(65) identified a small population of CD146+/CD45- cells (0.11%±0.02% of total human BM 
nucleated cells) that were clonogenic, displayed mural cell properties (including the expression 
of αSMA, NG2, calponin 1 and 3, and PDGFRβ), and, in vivo, were able to produce bone and 
organize a hematopoietic environment when transplanted to mice and to self-renew.  
Concurrently, Péault’s group published their classical paper identifying pericytes as 
progenitors of MSCs in multiple human organs and developed a methodology enabling their 
prospective purification using FACS  (13).  Specifically, because pericytes make up a relatively low 
fraction of cells in a tissue and, moreover, lack specific markers, their successful isolation required 
enzymatic digestion of tissue samples (they used adult and fetal skeletal muscle, placenta, 
adipose tissue, skin, myocardium, pancreas, and bone marrow) followed by FACS using a panel 
of antibodies to select cells expressing CD146+ after exclusion of hematopoietic (CD45), 
endothelial (CD34) and myogenic (CD56) populations (13). Reported abundance of human 
pericytes based on flow cytometry analyses ranged from <2% of total cells in skeletal muscle, 
pancreas or placenta to 14.6% in adipose tissue.  CD146+/CD45-/CD34-/CD56- human cells 
expressed a variety of pericyte markers (NG2, PDGFRβ and αSMA) and gave rise in culture to cells 
with MSCs features, including expression of typical MSC markers, migration in a culture model of 
chemotaxis, classical trilineage differentiation in vitro at the clonal level, and myogenic and 
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osteogenic differentiation in vivo in mice.  Alternative strategies to isolate pericytes have been 
reported including simplified versions of the antibody panel used by Crisan et al. (13)  in human 
(7,66) and mice (67) or the inclusion of additional antibodies (48) to isolate pericytes from human 
skeletal muscle. As such, cells have been isolated from human heart 
(CD146+/CD34−/CD45−/CD56−/CD117−) (68), umbilical cord (CD146+/CD45-/CD34-/CD56-)(69), 
skeletal muscle (alkaline phosphatase (ALP)+/ CD56-) (48) and endometrium (CD146+/PDGFRβ+) 
(70), while trace amounts of cells (0.04%) natively expressing MSC markers 
(CD105+/CD73+/CD90+/CD34-/CD45-) have also been detected  in human adipose (71). Some 
studies reported the use of single rather than a panel of antibodies to isolate human pericytes 
(66,72). Their results need to be interpreted with caution given the likelihood of inclusion of 
contamination by other cells (e.g. endothelial, hematopoietic and epithelial) that can significantly 
alter the characteristics of the populations obtained and provide equivocal data regarding clinical 
potential. In order to allow reliable comparison of results between studies, standardization of 
isolation procedures and cell culture conditions will be essential in future studies. 
 
Pericytes for regenerative medicine  
Numerous studies have investigated the potential of pericytes for human regenerative 
medicine primarily using rodent models (Table 1). Steps are also being made towards 
investigating their potential in veterinary medicine, specifically in relation to the horse, a 
recognized pre-clinical model for human musculoskeletal regeneration (33).  Consistent with the 
demonstrated involvement of native mouse pericytes in endogenous tissue repair (57,58), the 
inclusion of CD146+/NG2+/PDGFRβ+/CD45-/CD34-/CD56- human cells in engineered vascular 
9 
 
grafts improved patency rates and tissue remodeling, and promoted deposition of collagen and 
elastin (73). In addition transplantation of CD146+/CD34-/CD45-/CD56- human cells in a 
SCID/NOD mouse model of myocardial infarction promoted regeneration by significantly 
improving contractibility, increasing host angiogenesis and reducing ventricular remodeling, 
myocardial fibrosis, and chronic inflammation at the infarct site. Transplanted cells secreted high 
levels of trophic factors and cytokines including VEGF-A, PDGF-β, TGF-β 1, IL-6, LIF, COX-2, and 
HMOX-1 (68). The clinical regenerative potential of human pericytes has also been tested in 
muscle. CD146+/CD45-/CD34-/CD56- human cells from muscle, adipose or placenta (74) were 
injected into either cardiotoxin-injured gastrocnemius muscle of SCID/NOD mice or 
gastrocnemius muscle of Duchenne muscular dystrophy (SCID/mdx) mice producing human 
spectrin-positive myofibers (13) and dystrophin-positive myofibers (74), in addition to promoting 
angiogenesis. In another study, human CD146+/CD34-/CD45-/CD31- cells obtained from 
lipoaspirates decreased muscle atrophy following rotator cuff tears in immunodeficient mice 
(75). Human CD146+ cells from umbilical cord were also studied in a murine model of arthritis, 
showing increased therapeutic potential compared to CD146- cells (66). Pericytes have also been 
tested for healing of experimental bone defects. Specifically, adipose-derived human 
CD146+/CD45−/CD34−/CD31− (76) and mouse CD146+/NG2+/CD45- (67) cells showed similar 
regeneration potential to BM-MSCs in an atrophic non-union rat model and contributed to 
regeneration of large bone defects in a critical size bone defect in mice, respectively.  
The regenerative potential of human pericytes (CD146+/CD45−/CD34−) in combination with 
adventitial cells (CD146-/CD45−/CD34+) obtained simultaneously from the same stromal 
vascular fraction (SVF) preparations was also tested immediately after sorting in a critical-sized 
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calvarial bone injury model in immunodeficient mice, showing greater healing than when using 
unfractionated SVF (77). The combined use of the two different cell fractions in this and other 
studies (see below) was aimed at boosting cell numbers which, considering the relatively small 
numbers of each cell type normally obtained by FACS, would eventually allow transplantation of 
cells shortly after isolation avoiding the need for pre-expansion in culture (Fig. 2).   
Regardless, the positive effects consistently observed in these studies using different tissue 
regeneration settings demonstrate the potential of pericytes for clinical tissue repair and 
regeneration. Whether pericytes have greater clinical efficacy than culture-expanded MSCs or 
SVF extracts is still unclear at the moment as controlled comparisons between these cell types 
have rarely been performed (76,77). Thus, despite important advances made to date, far more 
investigation is needed to fully define the potential of pericytes for regenerative medicine, 
particular in relation to the advantage they may provide relative to unfractionated MSC 
preparations used currently. In addition, their clinical potential in veterinary species has not been 
assessed. 
 
Pericytes in veterinary species 
Given the promising results obtained using human pericytes in animal models of tissue 
regeneration, significant interest has also arisen in the isolation and characterization of pericytes 
from veterinary species, either for the purpose of developing improved regenerative therapies 
for companion animals or use in pre-clinical models of human regenerative medicine. Isolation 
and culture of pericytes from species other than human and rodents has been particularly 
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challenging due to the lack of specific antibodies, and only very recently were the first successful 
attempts reported (in sheep, horse and dog) (8,51,52).  
Horse – The widespread use of cell therapies in the horse (23,27,33,78-81) has fostered great 
interest in the characterization of MSCs with the ultimate aim of improving their therapeutic 
efficacy. Although a large number of studies have been devoted to this subject, no attempts had 
been reported until recently (8,50,82) to characterize different cell subpopulations with the aim 
of identifying subsets with optimum therapeutic properties. Earlier PCR (83) and flow cytometry 
(84) studies already reported the expression of the pericyte marker, CD146, in MSC preparations. 
More recently, we confirmed that indeed multiple pericyte markers (CD146, NG2, αSMA, 
PDGFRβ) are expressed by culture-expanded MSCs at least up to passage 8 (50). In addition, 
similar to results in humans, pericyte and MSC markers co-localized in different equine tissue as 
well as in cultured MSCs (8,50), overall indicating that pericytes give rise to equine MSCs in 
culture.  Following on these results, we used a FACS procedure similar to that described for 
isolation of human perivascular cells (13,85-87) to separately isolate pericytes (CD146+/CD144-
/CD45-/CD34-) and adventitial cells (CD146-/CD45-/CD144-/CD34+) from equine adipose SVF (8). 
We showed that, similar to findings in humans, native pericytes (as well as adventitial cells) could 
be successfully expanded in culture showing an MSC phenotype including multipotency and 
expression of specific MSC markers. Moreover, using chicken chorioallantoic membrane assay 
we showed that pericytes distinctly promoted angiogenesis in vivo and produce high levels of the 
angiogenic factors, VEGFA and ANGPT1, when compared with non-sorted SVF. Consistent with 
these findings, when co-cultured with endothelia, CD146+ cells became closely associated with 
vascular networks in vitro. Thus, given their ability to maintain a pericyte phenotype in culture, 
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especially in relation to their pro-angiogenic properties, CD146+ cells may be particularly useful 
for promoting tissue healing and improve the efficacy of current regenerative treatments in the 
horse. Further investigation is now needed to test the potential of these cells for specific 
applications including tendon repair, osteoarthritis, skin lesions and laminitis.    
Dog – Two different groups have reported on the isolation of pericytes from canine adipose 
tissue using FACS. In one study, a single anti-PDGFRβ antibody was used for which cross-reactivity 
validation was not reported (88). PDGFRβ+ accounted for 40% of cells in the original extract, a 
relatively high value compared with the yield of pericytes obtained by FACS in other studies 
(13,70), and suggesting contamination with PDFRβ-expressing cells other than pericytes (89). 
Moreover the immunophenotype and multipotency of the sorted cells were not established and 
therefore their actual nature is unclear. Nonetheless, subsequent experiments in a canine model 
of stroke concluded that intra-arterial delivery of autologous PDGFRβ+ cells following 
hyperosmolar mannitol administration was a feasible and safe therapeutic approach.  In a second 
study, IHC was performed to identify CD146+ cells in adipose tissue followed by isolation from 
SVF by FACS using a panel of antibodies, as previously described in other species (8,13,51), to 
isolate CD146+/CD45-/CD34- (pericytes) and CD146-/CD45-/CD34+ (adventitial cells) fractions.  
Characterization of each separate fraction was not reported but rather the two combined 
fractions were shown to be osteogenic in vitro and to produce trophic factors, VEGF, FGF-2 and 
PDGF, which expression was increased when cells were treated with the osteoinducer protein, 
NELL-1. The authors compared these with their previous findings with human cells and concluded 
that perivascular cells from dogs had less osteogenic potential than their human counterparts. 
Thus, although significant characterization of perivascular cells is yet to be performed in dogs, 
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the potential exists, as in the horse, for future clinical applications, particularly musculoskeletal 
disorders to which some breeds are particularly predisposed.     
Sheep – The sheep is a recognized orthopedic research model and in that regard ovine 
pericytes may be particularly useful for preclinical testing of novel musculoskeletal therapies.  
Péault’s group isolated pericytes (CD146+/CD45-/CD34-) from reportedly different ovine tissues, 
namely placenta, myocardium and adipose tissue, including infrapatellar fat pads (51). Unlike in 
some of the previous studies in humans and horse (8,87), depletion of endothelial cells was not 
performed due to lack of a suitable antibody, and no attempts were made to assess the level of 
endothelial contamination in the preparations obtained. Pericytes and adventitial cells (CD146-
/CD45-/CD34+) were characterized together, and both fractions showed characteristics of MSCs 
including multipotency. Autologous transplantation of the two combined cell fractions, after 
labelling with green fluorescence protein, to a cartilage defect was followed by engraftment into 
the articular tissue, although no repair was observed by 4 weeks. Thus, as in horse and dog, 
further studies are needed to establish the actual clinical potential of ovine perivascular cells and 
whether this would be valuable for preclinical studies on human regenerative therapies. 
Pig – The pig provides an extremely valuable model for degenerative conditions amenable to 
treatment with MSCs, most notably, cardiovascular disease. Nonetheless, in contrast to 
companion species and sheep, studies aimed at selectively isolating and characterizing pericytes 
as MSC precursors have not been reported.  Several studies reported the isolation of pericytes 
from porcine tissues using differential cell attachment to tissue culture vessels, a non-selective 
method (90,91). Although pericyte markers (αSMA, PDGFRβ and NG2) were identified in these 
preparations, their actual pericyte content is unclear, especially when sourced from 
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heterogeneous tissues such as skeletal muscle (90) and, critically, their MSC and regenerative 
properties were not reported. Due to the increased interest in the use of the pig not only as a 
pre-clinical model, but also for xenotransplantation, future efforts towards the systematic 
isolation and characterization of perivascular cells to assess their potential for tissue repair and 
immunodulation are expected. 
 
Conclusions 
The identification of perivascular cells as a native source of mesenchymal progenitor cells has 
opened the way to the development of novel regenerative therapies with improved efficacy using 
well-defined cell populations. Effective protocols for FACS-based isolation and in vitro expansion 
of human pericytes have been developed and significant clinical tissue regeneration potential has 
been shown for these cells using animal models.  Although successful isolation and culture of 
pericytes from other species (horses, dogs and sheep) has also been reported using similar 
methodologies, their potential for veterinary regenerative medicine and preclinical testing of 
human therapies remain largely unexplored. Critical to further progress in this area will be the 
validation and standardization of the procedures used to obtain cells from different species as 
well as the establishment of their therapeutic potential in different clinical settings, and the 
identification of reliable cell phenotype correlates of clinical efficacy.  It is hoped that such 
advances will result in improved therapies not only for humans but also for companion animals.   
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Figure legends 
Fig. 1 Equine pericytes. (A) Immunohistochemistry of testis showing the pericyte marker NG2 (in 
green) surrounding the endothelial layer visualized by staining with a CD144 antibody (in red). 
DAPI was used to stain cell nuclei. (B) Pericytes in culture grown in DMEM with 20% FBS and 1% 
penicillin/streptomycin. Scale, 50 µm, is indicated by white bars. (C) Flow cytometry histograms 
displaying fluorescence intensity vs event counts (corresponding to the number of cells) and 
showing displacement of cultured pericytes (dark line) stained with CD146 (pericyte maker) and 
CD29, CD90 and CD105 (MSC markers) compared with the respective isotype (grey). The 
antibodies used for the staining were: NG2 (MAB2585; R&D Systems), CD146 (MCA2141F; 
BioRad), CD29 (303015; BioLegend) and CD44 (MCA1082GA; Biorad). 
 
Fig. 2 Schematic representation showing tissue sources and cells tested for regenerative 
therapies. 
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 Table 1. Summary of regenerative therapy studies using isolated perivascular cells.   
 
Tissue of origin 
 
Markers used for cell sorting 
 
 
Regenerative model 
Human skeletal 
muscle 
CD146+/NG2+/PDGFRβ+/CD45-/CD34-
/CD56- 
Engineered vascular grafts implanted in rat aorta {He} 
Human skeletal 
muscle 
CD146+/CD34-/CD45-/CD56- Acute myocardial infarction in mice {Chen} 
Human placenta CD146+/CD45-/CD34-/CD56- Cell engraftment to the gastrocnemius muscle in mice 
{Park} 
Human lipoaspirate CD146+/CD45-/CD34-/CD31- Mouse model of rotator cuff tears {Eliasberg} 
Human umbilical cord CD146+ Collagen-induced arthritis in mice {Wu} 
Human adipose CD146+/CD45−/CD34−/CD31− Rat model of atrophic non-union fracture {Tawonsawatruk} 
Mouse adipose CD146+/NG2+/CD45- Mouse model of critical size bone defects {konig} 
Human adipose CD146+/CD45-/CD34- and CD146-/CD45-
/CD34+ 
Critical calvalial mouse injury model {James} 
Human skeletal 
muscle 
CD146+/CD34-/CD45-/CD56- Heart ischemia mouse model {Chen} 
Human saphenous 
vein 
CD31-/CD34+ Mouse myocardial infarction model {Katare} 
Dog adipose tissue PDGFRβ Canine model of stroke {Youn} 
Sheep infrapatellar fat CD146+/CD45-/CD34- and CD146-/CD45-
/CD34+ 
Sheep model of cartilage repair {Hindle} 
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